The heritability of Attention-Deficit Hyperactivity Disorder (ADHD) and its treatment by brain dopamine modulating medications, such as Adderall and Ritalin, raise the question as to whether risk for ADHD is impacted by improper control of dopamine availability or action. Dr. Blakely will discuss his group’s discovery of multiple, rare changes in a gene responsible for brain dopamine availability in individuals with ADHD, and how the study of these mutations suggests new insights into pathophysiological mechanisms and diagnostic strategies.
Watch webinar recording:
Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.
Sign up for other upcoming webinars.